Financial Support

86% of Patients Have $0 Financial Responsibility for Foundation Medicine Testing*

Foundation Medicine is committed to providing patients with resources and support throughout the testing process.

After your doctor orders a Foundation Medicine test and we receive your sample, we will contact you to share important information about what you can expect as your test moves forward. Foundation Medicine will make every attempt to obtain insurance coverage and payment for testing. Patient out-of-pocket costs will vary depending on your insurance. For those with out-of-pocket costs, financial assistance may be available for qualifying patients.** Anyone can apply at any time to see if they qualify. Complete an online form or this PDF application.

Or talk to a Client Services team member at:

Phone: 888.988.3639 | Email: client.services@foundationmedicine.com

* Financial assistance is only available for tests ordered within the U.S. and its territories.

** Data on File, Foundation Medicine, Inc., 2023. Based on US settled claims for FoundationOne®CDx, FoundationOne®Liquid CDx, FoundationOne®Heme, and PD-L1 IHC ordered from Foundation Medicine, reported between 1/1/22 and 3/31/23 before considering any financial assistance. 65% of commercially insured and 96% of Medicare and Medicare Advantage patients owe $0 for Foundation Medicine testing.

All Foundation Medicine tests are covered by Original Medicare and Medicare Advantage for qualifying beneficiaries.

Note: If you are an Original Medicare beneficiary, you may need to sign an Advance Beneficiary Notice (ABN) prior to the test order if you do not meet coverage criteria. Your doctor will determine if an ABN is required.

Note: If you are an Original Medicare customer, you may need to sign an ABN prior to the test order. Your doctor will determine if an ABN is required.

FoundationAccess® Program

Supporting you throughout the billing process is a top priority at Foundation Medicine—and FoundationAccess is here to help.

After we receive your test order, we start reviewing what your plan covers. For each comprehensive genomic profiling test ordered, we complete a benefits investigation and reach out to patients whom we expect may have out-of-pocket costs. Additionally, we support providers and patients by helping obtain prior authorizations when required, billing the patient’s health plan for the test, and appealing denials with the patient’s consent.

If there is patient responsibility for the test cost, patients who quality for financial assistance will have an out-of-pocket cost of up to $100 maximum per test.* You can apply at any time to see if you qualify. If you don’t qualify, payment plans may be available.

*Financial assistance is only available for tests ordered within the U.S. and its territories.

Apply for assistance

Fill out a financial assistance application online or download a PDF of the financial assistance application:

Important Safety Information

Select

FoundationOne CDx and FoundationOne Liquid CDx

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based in vitro diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. When considering eligibility for ROZLYTREK® based on the detection of NTRK1/2/3 and ROS1 fusions, or for TEPMETKO® based on the detection of MET SNVs and indels that lead to MET exon 14 skipping, testing using plasma specimens is only appropriate for patients for whom tumor tissue is not available for testing. Patients who are tested with FoundationOne Liquid CDx and are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com and www.F1LCDxLabel.com.